U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07159841) titled 'A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)' on Aug. 29.
Brief Summary: The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Congenital Adrenal Hyperplasia
Classic Congenital Adrenal Hyperplasia
Intervention:
DRUG: Atumelnant
Atumelnant, tablets, once daily by mouth, weight-based dosing
DRUG: Placebo
Placebo, tablets, once daily by mouth, weight-based dosing
R...